NCT07655934 A Mixed-Methods Metabolomics Investigation of Lifestyle and Energy Balance During Breast Cancer Survivorship
| NCT ID | NCT07655934 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Abramson Cancer Center at Penn Medicine |
| Condition | Breast Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2026-01-20 |
| Primary Completion | 2028-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2026-01-20 with a primary completion date of 2028-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The MILES Study is a longitudinal, mixed-methods investigation of urinary biomarkers, energy balance, and lifestyle modifications in diverse women during early breast cancer treatment. The study's overarching goal is to assess dietary quality and physical activity changes over time using reliable, scalable tools suitable for clinical or population settings, supporting newly diagnosed patients in adopting and maintaining healthy behaviors through treatment and survivorship.
Eligibility Criteria
Inclusion Criteria: * Adult women (age 18 years or older) * Able to read English or Spanish * Newly diagnosed with primary stage 0, I, II, or III breast cancer * Pathological diagnosis within the previous 60 days * Scheduled to have surgery with a Penn Medicine surgeon Exclusion Criteria: * Women age less than 18 years * Women without a new primary breast cancer diagnosis * Women who are pregnant
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07655934 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07655934 currently recruiting?
Yes, NCT07655934 is actively recruiting participants. Contact the research team at Julia.lewandowski@pennmedicine.upenn.edu for enrollment information.
Where is the NCT07655934 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT07655934 clinical trial?
NCT07655934 is sponsored by Abramson Cancer Center at Penn Medicine. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.